Amgen Mvasi, Kanjinti Sales Decline As Biosimilars Industry Faces New Policy Challenges
Executive Summary
ASP metric used in Medicare, and often in commercial insurance, for reimbursement of physician-administered drugs is an important factor in the sales arc for biosimilars. Price negotiations under IRA could bring their own margin-squeezing pain to pharmacy-benefit biosimilars.
You may also be interested in...
As Biosimilar Revenues Fall, Amgen Looks To Next Wave For Growth
With previously leading Amgen biosimilars such as Mvasi (bevacizumab) and Kanjinti (trastuzumab) seeing their sales decline, the firm is turning its attention to the next wave of biosimilars that will drive future growth.
HHS Price Negotiations Could Be Delayed When Biologics Have Biosimilars Pending Under Bill
Latest iteration of drug pricing legislation from Senate Democrats would also firm up the number of drugs HHS must choose for price negotiation each year and no longer treats insulin as a separate class for purposes of negotiation.
Strange Bedfellows: Generics Firms Join Big Pharma In Opposing Price Negotiation Legislation
Concerns that Medicare drug price negotiation provisions in the Build Back Better legislation would upend the generic and biosimilar industries might resonate with legislators more than complaints from branded drug companies.